RECURRENT PROSTATE CARCINOMA

This study is testing whether a dietary supplement made from white button mushrooms can help control prostate cancer. It is for men whose cancer has returned after initial treatment (showing rising PSA levels) and for men with newly diagnosed, low-risk cancer who are being monito…

This study is testing a two-part treatment for prostate cancer that has come back and spread to a few other places in the body. Participants receive hormone-blocking drugs for six months, along with a short, highly focused course of radiation aimed directly at the tumors. The goa…

This study is testing whether a combination of surgery and radiation can control prostate cancer that has returned or spread to a few other places in the body. It involves 20 men whose cancer has come back after initial treatment. The goal is to see if this targeted approach can …

This study is for men whose prostate cancer has returned after surgery. It tests if adding a drug called apalutamide to standard radiation therapy works better than radiation alone to keep the cancer from progressing. Apalutamide works by blocking hormones that can fuel prostate …

This study is testing whether adding two drugs (abiraterone acetate and prednisone) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has returned after surgery or radiation. The goal is to keep PSA levels low for longer after the 8…

This study is testing if a shorter, more intense course of radiation is safe and effective for men whose prostate cancer has returned or spread to a few lymph nodes. It compares two radiation methods—proton therapy and standard IMRT—to see which one causes fewer serious side effe…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This study is for men whose prostate cancer is starting to come back, shown by a rising PSA level, after their initial surgery or radiation. It compares two treatment plans: one uses a standard hormone-blocking drug (bicalutamide) alone, and the other combines that drug with an e…

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This study is testing if adding the immunotherapy drug pembrolizumab can help control advanced prostate cancer that has started growing again despite treatment with the standard drug enzalutamide. It involves about 58 men whose cancer has spread and is no longer responding to hor…

This study is testing the safety and effectiveness of combining two drugs, enzalutamide and cabazitaxel, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The goal is to see if using these drugs together can better c…

This study is testing if adding a common water pill called furosemide to a special imaging scan helps doctors see prostate cancer that has returned after surgery more clearly. The pill increases urine flow, which may wash away background signal in the bladder that can hide small …

This study aims to understand how the genetic makeup of prostate cancer changes when patients take a standard hormone therapy drug (abiraterone acetate). Researchers will collect tissue, blood, and urine samples from 92 men with advanced prostate cancer before and during treatmen…

This study investigates whether two common prostate cancer drugs (abiraterone acetate and enzalutamide) affect thinking, memory, and brain function. Researchers are following 100 men with advanced prostate cancer, using brain scans and cognitive tests to measure changes over time…